Rhythm Pharmaceuticals (RYTM) News Today $54.54 -0.12 (-0.22%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period JPMorgan Chase & Co. Sells 58,554 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)JPMorgan Chase & Co. decreased its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 41.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,592 shares of the company's sJanuary 18 at 3:19 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Rating of "Moderate Buy" by BrokeragesJanuary 13, 2025 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by AnalystsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and ten have given a buy ratingJanuary 13, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. trimmed its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 26.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,252 shares of the company's stock after selling 11,116 shares duriJanuary 13, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ: RYTM) Reports Strong Growth in Revenue and Clinical Development InitiativesJanuary 13, 2025 | americanbankingnews.comRhythm Pharmaceuticals price target raised to $60 from $58 at BofAJanuary 12, 2025 | markets.businessinsider.comRhythm Pharmaceuticals’ Strong Sales and Clinical Advancements Justify Buy RatingJanuary 11, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)January 10, 2025 | markets.businessinsider.comRhythm Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy RatingJanuary 10, 2025 | markets.businessinsider.comRhythm Pharmaceuticals Expects Higher Product Revenue For Full-yearJanuary 10, 2025 | markets.businessinsider.comRhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming MilestonesJanuary 10, 2025 | globenewswire.comPrincipal Financial Group Inc. Has $1.71 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Principal Financial Group Inc. raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 241.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32January 5, 2025 | marketbeat.comJefferies Financial Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)Jefferies Financial Group initiated coverage on shares of Rhythm Pharmaceuticals in a report on Thursday. They issued a "buy" rating and a $80.00 price objective on the stock.January 2, 2025 | marketbeat.comJefferies starts Rhythm Pharmaceuticals with Buy on obesity potentialJanuary 1, 2025 | markets.businessinsider.comRhythm Pharmaceuticals initiated with a Buy at JefferiesJanuary 1, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sees Large Volume Increase - What's Next?Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Strong Trading Volume - Still a Buy?December 23, 2024 | marketbeat.comRhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three yearsDecember 23, 2024 | uk.finance.yahoo.comRhythm Pharmaceuticals’ Promising Future: Buy Rating Reiterated Amid FDA Approval and Strategic ExpansionDecember 23, 2024 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday.December 23, 2024 | marketbeat.comRhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $69.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday.December 23, 2024 | marketbeat.comRhythm Pharmaceuticals initiated with an Outperform at OppenheimerDecember 21, 2024 | markets.businessinsider.comRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years OldDecember 21, 2024 | finanznachrichten.deFranklin Resources Inc. Has $13.03 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Franklin Resources Inc. raised its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 11.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 259,416 shares of thDecember 21, 2024 | marketbeat.comBarclays PLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Barclays PLC raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 79.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 106,397 shares of the company's stock after buyingDecember 21, 2024 | marketbeat.comFDA Expands Rhythm Pharma Obesity Drug Approval to Younger ChildrenDecember 21, 2024 | marketwatch.comStrategic Advancements and Market Potential Drive Buy Rating for Rhythm PharmaceuticalsDecember 21, 2024 | markets.businessinsider.comRhythm gets FDA approval for Imcivree for toddlersDecember 21, 2024 | msn.comOppenheimer Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform RecommendationDecember 21, 2024 | msn.comRhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years OldDecember 20, 2024 | globenewswire.comOppenheimer Initiates Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Friday. They set an "outperform" rating and a $76.00 price objective for the company.December 20, 2024 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have given aDecember 19, 2024 | marketbeat.comWellington Management Group LLP Decreases Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Wellington Management Group LLP cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 86.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,716 shares of the compaDecember 19, 2024 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Position Reduced by State Street CorpState Street Corp trimmed its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,993,166 shares of the company's stock after selling 10,716 shares duDecember 16, 2024 | marketbeat.comFmr LLC Grows Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Fmr LLC increased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 79.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,295 shares of the company's stock after purchasing an additional 22,306 shaDecember 15, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 10,882 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)BNP Paribas Financial Markets grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 307.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,425 shares of the company's stock after acquiring an additional 10,December 12, 2024 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Raised by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 1.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,416,952 shares of the company's stock after buying an additional 4December 10, 2024 | marketbeat.comNational Bank of Canada FI Sells 62,735 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)National Bank of Canada FI decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 15.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 341,507 shares of the company's stock after selling 62,735 shares during the quarDecember 10, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 4.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 225,373 shares of the company's stock afterDecember 8, 2024 | marketbeat.comRhythm Pharmaceuticals: A Key Year AheadDecember 7, 2024 | seekingalpha.comRhythm Pharmaceuticals price target raised to $75 from $64 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comRhythm Pharma: MHRA Expands Marketing Authorization For IMCIVREE - Quick FactsDecember 4, 2024 | markets.businessinsider.comHighVista Strategies LLC Purchases 23,064 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)HighVista Strategies LLC boosted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 160.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,426 shares of the company's stockDecember 3, 2024 | marketbeat.comRhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years OldDecember 3, 2024 | globenewswire.comIntech Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Intech Investment Management LLC purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,386 shares of the company's stoDecember 1, 2024 | marketbeat.comAlkeon Capital Management LLC Acquires 167,700 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Alkeon Capital Management LLC raised its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 16.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,167,700 shares of the company's stock after acquiring anNovember 29, 2024 | marketbeat.comVictory Capital Management Inc. Acquires 11,137 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Victory Capital Management Inc. grew its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 158.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 18,186 shares of the company's stock after acquiring an additional 11,137 sharesNovember 28, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Purchases 143,800 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Healthcare of Ontario Pension Plan Trust Fund grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 14.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,111,043 shares of theNovember 27, 2024 | marketbeat.comPenserra Capital Management LLC Makes New $1.31 Million Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Penserra Capital Management LLC purchased a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 25,063 shares of the company's stock, valNovember 27, 2024 | marketbeat.comAlgert Global LLC Decreases Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Algert Global LLC lowered its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 48.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 54,171 shares of the company's stock after selling 49,961 shares during the quarter.November 27, 2024 | marketbeat.comLoomis Sayles & Co. L P Invests $33.35 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Loomis Sayles & Co. L P bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 636,628 shares of the company's stock, valued at approximately $33,353,000. Loomis SaylesNovember 26, 2024 | marketbeat.com Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼0.710.64▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼67▲RYTM Articles Average Week Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Moderna News Today Intra-Cellular Therapies News Today Dr. Reddy's Laboratories News Today Catalent News Today Sarepta Therapeutics News Today Qiagen News Today Vaxcyte News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
